Anzeige
Mehr »
Dienstag, 01.07.2025 - Börsentäglich über 12.000 News
Nächster Kursturbo?: 226 % Plus seit Januar - wie weit kann diese Aktie noch steigen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14Z20 | ISIN: GB00BZ21RF93 | Ticker-Symbol: N/A
1-Jahres-Chart  (nicht börsennotiert)
STALLERGENES GREER PLC Chart 1 Jahr

Aktuelle News zur STALLERGENES GREER

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.06.Stallergenes Greer Showcases Developments in Respiratory and Food Allergy Care at EAACI 2025157Stallergenes Greer, a global leader in allergy therapeutics, will present insightful scientific developments at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, Glasgow...
► Artikel lesen
14.04.Stallergenes Greer: Positive Adherence Impact of IPUMP Connected Assistant for Sublingual Liquid Allergen Immunotherapy Treatment316Stallergenes Greer, a global leader in allergy therapeutics, will present positive results from its SPEED survey at the upcoming CFA congress (Congrès Francophone d'Allergologie, the French congress...
► Artikel lesen
04.03.Stallergenes Greer Announces Appointment of Andreas Amrein as Chief Executive Officer361Stallergenes Greer, a global leader in allergy therapeutics, today announced that the Board of Directors has appointed Andreas Amrein as Chief Executive Officer, with effect from April 1, 2025. After...
► Artikel lesen
09.01.Stallergenes Greer: European Commission Approves the Extension of the Indication of Palforzia to the Treatment of Toddlers With Confirmed Peanut Allergy321Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia® (defatted...
► Artikel lesen
06.01.Stallergenes Greer: Science Awards for Allergy 2025: Call for Applications317The Stallergenes Greer Foundation is pleased to announce the launch of the 2025 edition of its Science Awards for Allergy, an initiative dedicated to recognising outstanding contributions to allergy...
► Artikel lesen
02.12.24Stallergenes Greer: Positive CHMP Opinion for the Extension of Indication of Palforzia for the Treatment of Toddlers With Confirmed Peanut Allergy384Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
► Artikel lesen
30.07.24Stallergenes Greer: FDA genehmigt pädiatrische Indikationserweiterung für orale Immuntherapie Palforzia zur Behandlung von Erdnussallergien in den USA430Stallergenes Greer, ein weltweit führendes Gesundheitsunternehmen, das auf Allergen-Immuntherapien spezialisiert ist, gab heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA)...
► Artikel lesen
STALLERGENES GREER Aktie jetzt für 0€ handeln
30.07.24Stallergenes Greer: FDA Approves U.S. Pediatric Indication Extension for Palforzia Oral Immunotherapy for the Treatment of Peanut Allergy494Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy, today announced that the U.S Food and Drug Administration (FDA) has approved Palforzia [Peanut (Arachis...
► Artikel lesen
8 Nachrichten in den letzten 12 Monaten